These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28230618)

  • 1. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases.
    Gils A; Bertolotto A; Mulleman D; Bejan-Angoulvant T; Declerck PJ
    Ther Drug Monit; 2017 Aug; 39(4):308-315. PubMed ID: 28230618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.
    Strober BE; Armour K; Romiti R; Smith C; Tebbey PW; Menter A; Leonardi C
    J Am Acad Dermatol; 2012 Feb; 66(2):317-22. PubMed ID: 22243723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    Annese V; Vecchi M;
    Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
    Zheng MK; Shih DQ; Chen GC
    World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in rheumatology: current perspectives and lessons learnt.
    Dörner T; Kay J
    Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar medicines in inflammatory bowel disease.
    Moum B; Lundin KE
    Tidsskr Nor Laegeforen; 2014 Apr; 134(8):819-20. PubMed ID: 24780979
    [No Abstract]   [Full Text] [Related]  

  • 13. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
    Lapadula G; Ferraccioli GF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
    Peyrin-Biroulet L; Danese S; Cummings F; Atreya R; Greveson K; Pieper B; Kang T
    Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):731-738. PubMed ID: 31322440
    [No Abstract]   [Full Text] [Related]  

  • 18. [Biosimilars in rheumatology and other fields of medicine].
    Milchert M; Fliciński J; Brzosko M
    Postepy Hig Med Dosw (Online); 2014 Jul; 68():970-5. PubMed ID: 25055035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape of biosimilars in rheumatology.
    Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
    Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in inflammatory bowel disease.
    Moore GT
    Med J Aust; 2016 Oct; 205(7):294-5. PubMed ID: 27681963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.